🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Global Health Concern

The sexually transmitted infection are escalating globally, with figures suggesting in excess of 82 million infections each year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Public health authorities are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to major issues, including infertility. Researchers believe that specific application of this new drug will help slow the development of resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Results and Global Access

As per data detailed in a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the existing first-line therapy, which uses an injection and a pill. The research included nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to register and commercialise the drug in a wide range of developing nations.

Medical professionals treating patients have expressed optimism. Access to a one-pill regimen of this kind is described as a "revolutionary step" for gonorrhoea control. This is deemed crucial to lessen the impact of the illness for people and to prevent the spread of untreatable gonorrhoea globally.